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62. Summary 
Antipsychotic agents represent efficient therapy for serious psychiatric disorders, 
particularly schizophrenia, but also bipolar disorder, and are used by millions of 
patients worldwide. Metabolic adverse effects of antipsychotic drugs are thought to 
contribute significantly to the fact that life expectancy among schizophrenic patients 
is reduced with several decades. In particular, the so-called second-generation 
antipsychotics – most notably clozapine and olanzapine - significantly increase the 
prevalence of obesity, dyslipidemia, and type 2 diabetes. After initial cell culture 
experiments in our lab demonstrated that antipsychotic drugs activate lipid 
biosynthesis through the transcription factor SREBP, we set out to elaborate our 
findings in various preclinical model systems. Exposing glial-like and neuronal-like 
cultured cells to different antipsychotic agents, we showed that antipsychotics 
activated the expression of several SREBP-regulated genes encoding key enzymes in 
lipid synthesis with varying potency between the different drugs. The effects were 
much more potent in glial-derived than in neuron-derived cells, which is interesting in 
light of the fact that glial cells produce the bulk of lipids, essential in myelination and 
synaptic development, in the central nervous system.  
We then treated female rats with the metabolically potent antipsychotic agent 
olanzapine or with aripiprazole, which is considered metabolically neutral in humans, 
for two weeks. Olanzapine induced marked increase in food intake and significant 
weight gain in rats. By including olanzapine-treated rats with restricted access to 
food, which did not gain weight, we demonstrated that weight gain primarily relies on 
increased food intake. Aripiprazole, included as a negative control, yielded significant 
increase in food intake and weight gain. Notably, increased serum triglyceride levels 
were detected in all olanzapine-treated rats, independent of weight gain, while serum 
triglyceride elevation was not present in rats treated with aripiprazole. In olanzapine-
treated rats, serum triglyceride increase was accompanied by lipogenic activation in 
peripheral metabolic tissues, particularly in visceral adipose tissue.      
7In this 2-week experiment, we also included one treatment group receiving the 
modified fatty acid tetradecylthioacetic acid (TTA), a lipid-lowering agent, and one 
group treated with a combination of olanzapine and TTA. Despite olanzapine-induced 
weight gain in the olanzapine-TTA treatment group, TTA cotreatment led to 
significant reduction in lipid levels in serum and liver. In a follow-up experiment 
spanning 8 weeks, serum and lipid levels were similarly reduced in all rats receiving 
TTA, either as monotherapy or in combination with olanzapine or clozapine, in spite 
of weight-potentiating effects. In the liver, we found that TTA induced the 
transcription and activity of the key oxidative enzymes ACOX1 and CPT2, and 
downregulated transcription of HMGCR, the rate-limiting step in cholesterol 
synthesis. The effects of olanzapine monotherapy on food intake and weight gain 
wore off approximately three weeks into the experiment, and serum triglycerides were 
not elevated in olanzapine-treated after 8 weeks of treatment. Clozapine, unlike in 
humans, did not induce weight gain. We concluded that improved dosing regimens 
are necessary in order to maintain dysmetabolic effects of antipsychotic in rat in the 
long term and thus increase the relevance of this animal model. The concomitant 
weight gain potentiation and lipid-lowering effects of TTA, on the other hand, further 
supported the presence of independent mechanisms regulating body weight and lipid 
levels. These parameters may not be fully disconnected, however, as one potential 
mechanism suggested by us to underlie favourable lipid values was increased adipose 
tissue mass, providing storage capacity for surplus lipids.  
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5. Introduction 
5.1 Schizophrenia  
5.1.1. Historical aspects 
Schizophrenia is probably the psychiatric diagnosis surrounded by the most persistent 
mythical beliefs and the most resistant prejudice. In Norway, the adjective 
“schizophrenic” is quite frequently used in order to describe equivocal or inconsistent 
actions, statements or situations, demonstrating that members of the public confuse 
schizophrenia with the far less common dissociative identity disorder (formerly 
known as multiple personality disorder). The fact that the term “schizophrenia” 
originally means “split mind” may have contributed to this misconception. When 
Eugene Bleuler introduced the term in 1908, he used the German words “Zerreißung” 
(tearing) and “Spaltung” (splitting) in order to describe the core concept of a group of 
“syndromes” (i.e., constellations of symptoms) characterized, among other 
pathological manifestations, by disintegrated psychological association processes 1. 
He elaborated on the concept of “splitting” in his famed 1911 work on schizophrenic 
disorders, “Dementia praecox oder gruppe der schizophrenien”, and defined several 
other classic symptoms of schizophrenia, such as psychotic symptoms (“a predilection 
for fantasy”), disrupted affective abilities and “autism”, a severe loss of interest in the 
surroundings 1.  
5.1.2 Clinical manifestations 
At present, the most commonly used diagnostic criteria for schizophrenia are found in 
the diagnostic manuals published by the American Psychiatric Association 
(Diagnostic and Statistical Manual of Mental Disorders, 4th  edition - DSM-IV), or by 
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the World Health Organization (International Statistical Classification of Diseases 
and Related Health Problems, 10th revision - ICD-10) 2, 3. DSM-IV lists 5 diagnostic 
subgroups for schizophrenia, with the common features of “disturbances in thought, 
perception, affect, behaviour, and communication that last longer than 6 months.” In 
addition, patients must exhibit so-called “active phase symptoms” for at least 1 of 
these 6 months (unless successfully treated). Active phase symptoms include 
psychotic symptoms, such as hallucinations (often auditory) and delusions, odd 
beliefs, or bizarre perceptual experiences. Such symptoms, representing features not 
seen in healthy individuals, are often characterized as “positive symptoms”. In the 
other end of the spectrum, “negative symptoms” are also hallmarks of schizophrenia. 
This term is used to describe the absence of emotions, thoughts or behaviour desirably 
present in healthy individuals, and may manifest as social withdrawal, affective 
flattening, apathy, or anhedonia. Patients may present with additional symptoms such 
as disorganized speech and/or disorganized or catatonic behaviour. Impairment of 
cognitive capabilities is also recognized as an important aspect of schizophrenia. Most 
patients with schizophrenia experience recurring psychotic episodes throughout their 
lives.  
5.2 Epidemiological aspects of schizophrenia 
5.2.1 Incidence and prevalence  
The lifetime risk of schizophrenia has traditionally been given at ~1% worldwide. 
Estimates of incidence (i.e., the number of new cases in a given population per year) 
depend on a large number of factors such as diagnostic criteria, the diagnostic 
methods used, the organisation of local health care systems, and demographic 
elements such as general mortality and migration 4. Thus, incidence estimates vary 
between studies. Stringent diagnostic criteria yielded incidence rates ranging from 
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6/100,000 to 14/100,000 in a large multinational WHO study (the so-called 10-
country study) 5. One of the conclusions in this study was that the incidence of 
schizophrenia shows little variation across populations. However, the question of 
whether the 10-country study was designed in a way that would ensure the detection 
of differing incidence between populations has been raised, and the results sparked 
much debate 6. Recently, a meta-analysis indicated an overall median incidence of 
schizophrenia of 15,2 per 100,000, with an estimated 7 out of 1000 individuals 
diagnosed with the disorder at some point in their life 7. This and other studies 
indicate that average lifetime prevalence across all populations may be slightly lower 
than the conventional 1% estimate, and that schizophrenia may be less uniformly 
distributed than previously thought 7-9. Furthermore, contrasting former beliefs of 
even gender distribution, meta-analyses have revealed that the male:female risk ratio 
of developing schizophrenia may be ~ 1.4:1 10, 11.  
5.2.2 Costs of schizophrenia  
Due to factors such as early symptom debut (i.e., early twenties), protracted course 
and complex treatment schemes, the economic burden of schizophrenia is 
overwhelming. An estimated 1,5-3% of health care and social spending of developed 
countries is accounted for partly by direct costs, such as expenses for treatment, and 
partly by indirect costs (e.g., lost productivity) of schizophrenia 12. In addition, non-
quantifiable losses of social and psychological character affect patients and family 
members alike. In statistics generated by the WHO, schizophrenia is listed as the 5th
and 6th most significant cause of years lived with disability (YLD) in men and 
women, respectively 13.
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5.2.3 Risk factors for schizophrenia 
Twin and adoption studies have provided clear evidence that the heritability of 
schizophrenia is high, perhaps as high as 80% according to one meta-analysis 14. 
Conventionally, a heritable, “intrinsic” vulnerability is thought to coincide with 
“external” risk factors to trigger the onset of the disorder in an individual. Generally 
accepted “external” risk factors include being born during the winter, high paternal 
age, obstetric complications, prenatal viral infections, and cannabis use 8. The 
disorder is often characterized as “multifactorial”, meaning that several circumstances 
must coexist in order to trigger symptoms.  
Conscious of the high heritability, researchers have attempted to identify 
susceptibility genes for schizophrenia, i.e. genes in which defects (mutations) could 
increase the risk of suffering from the disorder. The Schizophrenia Research Forum 
(http://www.schizophreniaforum.org) maintains a list of the genes presently found to 
have the strongest association with schizophrenia. The latest ranking (April 2011) is 
topped by the genes PRSS16 (PRSS16 protease, serine, 16), PGBD1 (piggyBac 
transposable element derived 1), and NRGN (neurogranin (protein kinase C substrate, 
RC3) 15.  
5.2.4 Neurochemical paradigms of schizophrenia 
The pathophysiology of schizophrenia, despite eager research, remains elusive. The 
most influential paradigm in neuromolecular schizophrenia research during the last 40 
years has undoubtedly been the so-called dopamine hypothesis. Early versions of this 
theory were based on the fact that several drugs relieving schizophrenic symptoms 
bind to, and block, dopamine receptors (particularly D2 receptors) in the brain, as 
discussed below 16. Thus it was suggested that cerebral dopaminergic “overdrive” is 
an essential component of the pathophysiology of schizophrenia. Later versions of the 
dopamine hypothesis proposed differential dopaminergic dysfunction in neuronal 
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subpopulations, with elevated mesolimbic (subcortical) dopaminergic signalling 
possibly underlying positive symptoms, and reduced dopaminergic activity in the 
prefrontal cortex theoretically causing negative symptoms 17. It has been suggested 
that the prefrontal hypodopaminergic state may actually cause an increase in striatal 
dopaminergic signalling 17. More recently, dysfunction in other neurotransmitter 
systems, such as the glutamatergic and GABAergic systems, have also been 
implicated 16. Possible defects in several aspects of neuronal signalling are integrated 
in the so-called neurodevelopmental hypothesis, which focuses on 
embryonic/developmental defects in synaptic density and other aspects of neuronal 
function 16. Demyelination, i.e. loss of myelin, the primary component of white 
matter, affects neuronal connectivity and is thought to be of significance in the 
pathophysiology of schizophrenia 18, 19. In the CNS, myelin is synthesized by 
oligodendrocytes, a type of glial cells embedding neurons, to facilitate neuronal 
conductivity 20. Signs of impaired myelination have been demonstrated in patients 
with schizophrenia 18, 21, 22, and may either result from reduced myelination during late 
adulthood or degenerative processes during the course of the illness itself.  Most 
relevant studies include schizophrenic patients receiving pharmacological treatment 
for schizophrenia, an important confounder which is difficult to avoid, but often 
deemphasized in the interpretation of results.  
  
5.3 Antipsychotic drugs 
5.3.1. Early history of pharmacological therapy for psychiatric disorders 
Historically, medicine had little to offer patients suffering from psychosis or other 
severe psychiatric symptoms. Often, treatment was characterized by more or less 
desperate attempts to ameliorate suffering and prevent patients from inflicting injury 
on themselves or others. Methods of treatment such as lobotomy, insulin shocks (the 
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induction of a hypoglycaemic state leading to loss of consciousness) or “sleep cures” 
(prolonged comatose states induced by barbiturates or similar agents) were employed 
during the first half of the 20th century 23, 24. Treatment attempts such as these, which 
may seem primitive and ill-considered to us, must be viewed in light of the scarce 
options available at the time. Some patients actually appear to have improved, or at 
least to have experienced blunted positive symptoms, after receiving unspecific 
pharmacological treatment employed in order to achieve general sedation 24, 25. 
Nevertheless, the fact remains that many types of treatment administered to the 
mentally ill caused considerable harm or even fatal outcome; for instance, “sleep 
cures” had a 5% mortality rate 24. 
Throughout the 1950s, several pharmacological agents specifically improving 
psychotic symptoms were introduced, and rapidly made their way into clinical 
practice. Reserpine, an alkaloid isolated from the dried root of the shrub Rauwolfia 
serpentina, predated the drugs presently regarded as antipsychotic agents. In India, 
Rauwolfia serpentina was reportedly used to treat “insanity” long before being 
introduced to the Western world as an antihypertensive agent in the late 1940s 26. 
Indeed, in addition to its antihypertensive properties, reserpine was found to possess 
antipsychotic properties 27. However, reserpine never gained widespread use as an 
antipsychotic agent due to unacceptable side effects (hypotension and, importantly, 
depression 28), and due to the introduction of other pharmacological agents with 
antipsychotic properties.  
5.3.2 First-generation antipsychotics 
The first specific antipsychotic agent was chlorpromazine, a phenothiazine 
synthesized in 1950 26. Commercially introduced as a treatment for psychiatric 
illnesses in 1953, chlorpromazine is considered the prototype antipsychotic agent, and 
the first of the so-called “typical”, or first-generation, antipsychotics 29. Its 
introduction has been described as a revolution by psychiatrists who, for the first time, 
observed specific treatment-induced regression of positive symptoms in patients with 
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schizophrenia 25. Haloperidol, synthesized in 1958 and commercially launched in 
Europe in 1959, belongs to a different chemical class than chlorpromazine, namely 
the butyrophenones 29. Several other antipsychotics were also introduced during the 
1950s and 1960s (Table 5.1). During the 1970s, experiments revealed that all 
antipsychotic agents known thus far were characterized by high affinity for 
dopaminergic receptors, blocking such receptors in the brain and thereby inhibiting 
the binding of dopamine 30. In particular, dopamine D2 receptor antagonism seemed 
essential in terms of antipsychotic effect; drugs lacking this property have later been 
demonstrated to have inferior effect on psychotic symptoms 31, 32. Chlorpromazine is a 
relatively weak D2 antagonist compared to other early antipsychotics, while 
haloperidol is a potent D2 blocker 33, 34.  
Drug Chemical group Commercially introduced Current trade names 1
Chlorpromazine Phenothiazine 1953 (Largactil)2
Perphenazine Phenothiazine 1957 Trilafon 
Haloperidol Butyrophenone 1959 Haldol 
Zuclopenthixol Thioxanthene 1962 Cisordinol 
Table 5.1 Selected first-generation (typical) antipsychotics 35.
The correlation of D2 affinity with antipsychotic effect is now well established; D2
occupancy above a certain threshold is required in order to achieve clinical 
antipsychotic effect 36. However, several dopaminergic pathways with physiologically 
                                             
1 Norway 
2 Not for standard sale in Norway (2011) 
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distinct functions exist in the brain, and D2 occupancy yields site-specific clinical 
effects 32. During clinical trials and early clinical use, it became evident that both 
chlorpromazine, haloperidol and other typical antipsychotic agents induce severe 
dose-dependent extrapyramidal side effects, including akathisia (an intense feeling of 
restlessness or unease), Parkinsonism, dystonias, and tardive dyskinesia 34, 37. The 
propensity to induce these adverse effects is correlated with D2 affinity in the 
striatum, and dopaminergic blockade in this area of the brain is thought to be the main  
cause of extrapyramidal side effects 32.  
5.3.3 Second-generation antipsychotic agents 
The serious adverse effects associated with typical antipsychotic agents encouraged 
the search for new antipsychotics. Clozapine, the first of the so-called second-
generation antipsychotic agents, was synthesized in 1958 (i.e., the same year as 
haloperidol) patented in Schwitzerland in 1960, but not introduced clinically in 
Europe until 1972, and in the USA in 1990 (reviewed in 38, 39). Second-generation 
antipsychotics are frequently designated “atypical” and viewed as a group, despite 
pharmacological heterogeneity. In general, the most distinct differences between first- 
and second-generation drugs result from variations in D2 and serotonin (5-
hydroxytryptamine, 5-HT) receptor affinity. Several second-generation agents occupy 
90-100% of 5-HT2 receptors, with 5-HT2A antagonism not observed for typical 
agents, while the degree of D2 blockade is generally lower than among the typical 
antipsychotics 32, 36. Accordingly, the risk of extrapyramidal side effects is 
significantly lower in patients treated with second-generation than in those treated 
with first-generation antipsychotics. For instance, clozapine binds D2 receptors much 
more weakly than do first-generation drugs, while its affinity for serotonergic 
receptors (5-HT2A, 5-HT2C) is as much as 20 times higher than its D2 affinity 31, 36, 40. 
Unfortunately, treatment with clozapine carries a risk of agranulocytosis (a sharp 
decline in the number of circulating white blood cells, with resultant risk of 
infection), a potentially lethal adverse effect 41. After being withdrawn from the 
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market in 1975 due to the risk of agranulocytosis, clozapine was relaunched in the 
USA in 1990 after clinical studies demonstrated its superiority over typical 
antipsychotic agents in treatment-resistant cases of schizophrenia 42. At present, 
however, other atypical drugs are commonly regarded as primary choices in newly 
diagnosed psychoses. 
Drug Chemical group Commercially 
introduced 
Current trade names 
(Norway) 
Clozapine Dibenzodiazepine 1972 Leponex, Clozapin, Clozapine 
Risperidone Benzisoxazole 1994 Risperdal, Risperidon 
Olanzapine Thienobenzo-
diazepine 
1996 Zyprexa, ZypAdhera, 
Olanzapin 
Ziprasidone Benzisothiazolyl 2001 Zeldox 
Aripiprazole Quinolone 2002 Abilify 
Quetiapine Dibenzothiazepine 1998 Seroquel, Quetiapin 
Amisulpride Benzamide 1990 Solian 
Table 5.2 Second-generation (atypical) antipsychotics 35. Aripiprazole has been called the 
first “third-generation” antipsychotic due to its properties as a partial D2 agonist.
Olanzapine, approved by the American Food and Drug Administration (FDA) in 
1996, is chemically related to clozapine 43. Reminiscent of clozapine’s properties, 
olanzapine’s affinity for 5-HT2 receptors exceeds its affinity for D2 receptors, with an 
in vitro 5-HT2/D2 affinity ratio approximating 12 40. Imaging studies have 
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demonstrated that olanzapine’s D2 affinity is higher than that of clozapine 36. 
Agranulocytosis has rarely been reported in patients treated with olanzapine 44. 
However, relatively soon after the drug’s introduction, reports of severe metabolic 
side effects surfaced; these effects are discussed below 45. Ziprasidone, marketed 
since 2001, is another atypical antipsychotic, with D2 affinity comparable to that of 
risperidone as well as high affinity for several 5-HT receptors, combined with 
serotonin and noradrenaline reuptake inhibition 46. Aripiprazole, commercially 
available from 2002, is frequently referred to as the first “third-generation” 
antipsychotic. This agent’s pharmacological properties deviate from that of prior 
antipsychotics in that it is a partial D2 agonist (or possibly possessing “functionally 
selective” D2 affinity) rather that a “traditional” D2 antagonist 47. Aripiprazole also 
possesses partial agonism at 5-HT1A receptors, as well as 5-HT2 antagonism.  
5-HT1a 5-HT2A 5-HT2C D1 D2 Į2C ĮA1 Į1B ȕ2 M1 M3 H1 
Chlorpromazine (+) +++ ++ + +++ ++ ++++ ++++ + ++ ++ ++++
Haloperidol (+) ++ 0 ++ +++ + ++ +++ 0 0 0 (+) 
Risperidone + ++++ ++ + +++ +++ +++ +++ 0 0 0 ++ 
Olanzapine (+) +++ ++ ++ ++ ++ + + 0 ++ ++ +++ 
Clozapine + ++ ++ + + ++ +++ +++ 0 ++ ++ +++ 
Quetiapine + + (+) + + ++ ++ ++ (+) + (+) +++ 
Aripipazole +++ +++ + + ++++ ++ ++ ++ 0 (+) (+) ++ 
Ziprasidone ++ +++ ++ ++ +++ ++ ++ +++ (+) 0 0 + 
Table 5.3 Receptor binding profiles of various antipsychotic agents. 0: no affinity; (+) very 
weak affinity; + weak affinity; ++ intermediate affinity; +++ strong affinity; ++++ very 
strong affinity for the receptor subtype, reflected in darkening colour gradient.  Adapted from 
31. 5-HT: 5-hydroxytryptaminergic (=serotonergic); D: dopaminergic; Į,ȕ: subtypes of 
adrenergic receptors; M: muscarinic, H: histaminergic.
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5.3.4 Metabolic adverse effects of antipsychotic drugs 
Metabolic disturbances, including weight gain, are recognized adverse effects of 
typical antipsychotic drugs, both phenotiazines and, to a moderate degree, 
haloperidol, as reviewed in 48, 49. Glucose dysregulation, occasionally debuting as 
ketoacidosis, was also observed in patients treated with typical antipsychotics 50, 51, 
and increased serum cholesterol was described in patients treated with 
chlorpromazine in 1967 52. With increasing use of clozapine and olanzapine, however, 
it soon became evident that these antipsychotics induce more frequent and more 
serious metabolic dysfunction than older drugs, and this issue has gained increasing 
attention during the last decades. Early clinical studies on clozapine mention weight 
gain as an adverse event 53, 54. Several years later, elevated serum triglyceride levels 
were reported in patients treated with clozapine 55-57.  Reports on olanzapine’s adverse 
effect profile published in the late 1990s, while describing low risk of dyskinesias and 
hematotoxicity, also mention the risk of weight gain 58, 59, later demonstrated to occur 
due to increased adipose tissue mass 60, 61. For olanzapine and clozapine, a frequently 
cited meta-analysis estimated an average short-term weight gain (10 weeks) in the 
range of 3.5-4 kg, with continued weight gain at least during the first year of 
treatment – in one study, 80% of first-episode psychotic patients receiving olanzapine 
gained >7% of pre-treatment body weight during the first 52 weeks of treatment 62.  
During the early years of olanzapine availability, the implications of metabolic 
adverse effects remained unclear (“the significance of this [i.e., weight gain] beyond 
cosmetic effects is unknown” 63), but the first reports of olanzapine-induced 
hypertriglyceridemia were published during the same period 63-65. Average 
olanzapine-induced increase in serum triglycerides is often given at 30-50%, while 
increase in serum cholesterol levels has also been reported during clozapine and 
olanzapine treatment 57, 65, 66. Furthermore, both clozapine and olanzapine have been 
demonstrated to increase the risk of insulin resistance and type 2 diabetes 66-69. 
Consequently, atypical antipsychotics significantly increase the risk of developing the 
constellation of parameters often termed the metabolic syndrome (Table 5.4).  
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Parameter Males Females 
Waist circumference 94 cm* 88 cm* 
Serum triglycerides >1,7 mmol/l >1,7 mmol/l 
Serum HDL <1,03 mmol/l <1,29 mmol/l 
Blood pressure Systolic >130 or diastolic >85 mmHg 
Fasting serum glucose > 5,6 mmol/l or recognized type 2 diabetes 
Table 5.4. Patients with central obesity plus any two of the findings described above fulfil 
the criteria for the diagnosis of metabolic syndrome 70. * Europids. 
The risk of weight gain, serum lipid increase and glucose dysregulation is generally 
regarded as intermediate for the second-generation agents risperidone and quetiapine, 
and low for aripiprazole and ziprasidone 49, 62, 65, 69, 71-73. In fact, replacing olanzapine 
with aripiprazole has been shown to significantly improve the metabolic status of 
patients 74.  
5.3.5 Clinical implications of metabolic adverse effects 
Mortality rates among patients with schizophrenia are markedly increased compared 
to those found in the general population, causing patients with serious mental 
disorders to lose 2-3 decades of life on average 7. This is partly due to increased 
suicide rates and increased susceptibility to fatal accidents, but most importantly due 
to early death from somatic conditions, with cardiovascular disorders as the single 
most common cause of death 7, 75, 76. Compared to the general population, patients 
with psychiatric disorders may have a higher background risk of developing the 
metabolic syndrome, which may lead to cardiovascular disorders 77, 78. Failure to seek 
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medical care or attend screening programmes, life style issues among patients 
(smoking, sedentary life style), and inadequate attention from caregivers concerning 
somatic comorbidity are probably important causes 75, 76, 79. This complicates the 
interpretation of data regarding the contribution of antipsychotics to metabolic risk, 
particularly as some reports on metabolic dysfunction in schizophrenic patients 
include patients having received antipsychotic agents 80. However, numerous studies 
indicate that treatment with antipsychotics adds significantly to the mortality rates in 
patients with serious mental disorders 69, 75, 81, 82. Metabolic dysfunction, particularly 
weight gain, is also a potential cause of non-adherence, increasing the risk of 
psychotic relapse  83.  
In addition to patients with schizophrenia, many individuals diagnosed with other 
psychiatric disorders, e.g. bipolar disorder, may respond well to antipsychotic drugs 
84. According to Eli Lilly’s 2008 sales figures, the company made $4.7 billion from 
worldwide sales of olanzapine that year 85. In Norway, official sales figures show that 
15,649,516 DDD (estimated average daily dose for an adult patient) of antipsychotic 
agents were prescribed in Norway in 2008 86. Consequently, a very large number of 
patients worldwide receive antipsychotic treatment and are thus at risk of developing 
metabolic adverse effects. 
5.3.6 Can receptor binding profiles explain metabolic adverse effects? 
Increased food intake, primarily due to impairment of satiety onset, is thought to be 
the main underlying cause of weight gain induced by antipsychotic agents, and has 
been demonstrated both in humans 81, 87 and in rodents 88-90. At present, no consensus 
exists in terms of the pharmacological properties underlying hyperphagia and other 
metabolic adverse effects, or the intracellular signalling pathways through which they 
are mediated. Several antipsychotic agents have antihistaminergic properties 31, and 
affinity for histaminergic (H1) receptors correlates with weight gain 91, 92. H1
antagonism is linked to increased food intake 91, suggestedly through H1-mediated 
activation of AMP-activated protein kinase (AMPK) in the hypothalamus 93. The 
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involvement of several other receptors (serotonergic 5-HT2C, adrenergic Į1 and Į2 
receptors, and muscarininc M3 receptors) has also been implicated in antipsychotic-
induced weight gain 89. The complex receptor binding profiles of antipsychotic drugs 
(Table 5.3) complicate the identification of one or several receptors primarily 
responsible for weight gain 94, and predictions of weight gain risk based on receptor 
binding profiles are sometimes unsuccessful. For instance,  ziprasidone, which is 
recognized not to induce significant weight gain in humans, possesses both 5-HT2C
antagonism (high) and H1 affinity (moderate) 95, and would thus be expected to 
induce weight gain. Notably, some antipsychotics with weak affinity for H1 receptors, 
e.g. haloperidol, are known to cause moderate weight gain 31, 49, 91. Thus, a well-
defined receptor binding profile resulting in increased risk of weight gain has yet to 
emerge. Regarding other dysmetabolic adverse effects, H1, 5-HT2C, and M3 receptors 
has been linked to derangements in glucose metabolism, while no receptor binding 
profile has been defined as far as dyslipidemia is concerned 96, 97.  
5.3.7 Animal models for antipsychotic-induced metabolic adverse effects 
In the exploration of the molecular mechanisms underlying metabolic adverse effects, 
a reliable animal model is instrumental. Rodent models of antipsychotic treatment 
have been extensively explored, with two major challenges surfacing during the two 
last decades. Firstly, the degree to which each specific antipsychotic agent induces 
metabolic side effects differ, in some cases, between human and rodent, particularly 
with regard to weight gain. Secondly, in rodents, antipsychotic-induced weight gain is 
sex-dependent, i.e. observed almost exclusively in females (Table 5.5). Conclusive 
evidence for gender differences in the risk of developing antipsychotic adverse effects 
has not been found in humans 98, 99. As described above, olanzapine and clozapine are 
the antipsychotic agents most prone to induce massive weight gain and related 
dysmetabolic features, such as dyslipidemia, in patients 49, 51, 100, 101. In female rats, 
elevated food intake and weight gain through increased adipose tissue mass during 
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short-term treatment with olanzapine (1-10 mg/kg) are well characterized, even in 
animals receiving standard rodent chow with high carbohydrate and low fat content 89, 
102, 103. Olanzapine has also been demonstrated to have hyperphagic effects in male 
rats 88, 104, 105. Furthermore, studies in male rats have shown that subchronic treatment 
with olanzapine increases adipose tissue mass, but not body weight, using diets with 
medium to high fat content 106, 107. One study in which olanzapine-treated male rats 
received standard laboratory chow also reported increased adipose tissue mass in the 
absence of hyperphagia and body weight gain after 20 days of olanzapine treatment 
105.  
As for clozapine, with a clinical metabolic profile similar to that of olanzapine 69, 
hyperphagia has been reported in male rats receiving a clozapine dose of 0.3 mg/kg 88. 
Weight gain has not been demonstrated in rats of either gender treated with 0.5-8 
mg/kg 108, 109, but was reported in one 28-day study in female rats treated with 20 
mg/kg clozapine 110. In contrast, clozapine has somewhat unexpectedly been reported 
to induce weight reduction in rats at doses of 6-10 mg/kg 109, 111. Reminiscent of 
observations from olanzapine-treated male rats, clozapine treatment has been shown 
to induce adiposity in female rats, with no effect on weight gain, except in one study 
reporting weight gain in male rats receiving clozapine 20 mg/kg for 7 weeks 111, 112. 
Aripiprazole, considered metabolically neutral in patients, has been demonstrated in 
one study to induce moderate weight gain in female rats (8 mg/kg) 103, while 
apparently weight-neutral in a similar experiment using aripiprazole a dose of 2.25 
mg/kg 113. In agreement with the latter report, an aripiprazole dose of 2 mg/kg failed 
to induce hyperphagia in female rats 114. Ziprasidone, also regarded metabolically 
neutral in patients, has not been demonstrated to possess hyperphagic effect in rat, 
although some groups have reported moderate weight gain in female rats at relatively 
low doses (2-10 mg/kg) 115-117.  
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Olanzapine Clozapine Aripiprazole Ziprasidone 
ƃ Ƃ ƃ Ƃ ƃ Ƃ ƃ Ƃ
Weight  
gain 
ļ 105-
107, 118
Ĺ 119
Ĺ89, 102, 
103, 118
ļ/Ļ 108, 
109, 118
Ĺ 112
ļ/Ļ 108, 
109, 111, 118
Ĺ 110
Ĺ103
ļ 113
ļ 106 Ĺ 117
Adipose mass Ĺ105-107 Ĺ103 Ĺ111 ļ 113 Ĺ 106
Hyperphagia Ĺ 88, 105
ļ105
Ĺ 103, 
120
Ĺ88
ļ 118
ļ 111, 118 ļ 114 ļ 106
Serum 
triglycerides 
ļ 103, 
115, 121
    ļ 106 ļ
115
Glucose 
dysmetabolism 
Ĺ 122, 123 Ĺ 124 Ĺ 122, 123    ļ 122, 
123
Table 5.5 Overview of dysmetabolic features demonstrated in rats. Ĺ: increase observed 
relative to vehicle. ļ: no change observed relative to vehicle. Ļ decrease observed relative to 
vehicle. 
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Few studies have reported lipid levels in rodent experiments. Serum triglycerides have 
largely been reported as unaltered by olanzapine 103, 115, 121, while increased serum free 
fatty acids after treatment with this drug have been shown in one experiment 103. 
Derangements in glucose metabolism have been thoroughly demonstrated in rats 
treated with olanzapine and clozapine 122-124. In female mice, the same pattern as in 
rats, with olanzapine-induced weight gain, has been demonstrated 125. A few studies 
have also shown olanzapine-induced increase in serum triglycerides in female mice 
126, 127.  
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5.4 Lipid metabolism 
5.4.1 General aspects of lipid metabolism 
Lipids constitute a large group of molecules involved in numerous essential processes 
and structures in the human organism. Fatty acyls (fatty acids), mono-, di-, and 
triglycerides, phospholipids and sterol-containing molecules, such as cholesterol, all 
belong to this class of macromolecules. A short overview of relevant aspects of lipid 
metabolism is presented below.  
5.4.2 Free fatty acids and triglycerides 
In times of excess, energy is primarily stored as triglycerides in adipose depots 128. 
Lipids may be absorbed from the diet or synthesized de novo from pyruvate 128. De 
novo synthesis primarily occurs in the liver, from which triglycerides are exported to 
white adipose tissue. The committed step in fatty acid synthesis is the formation of 
malonyl-CoA from acetyl-CoA, synthesized by acetyl-CoA carboxylase 1 (ACC1) 
(Figure 5.1) 128. Malonyl-CoA then undergoes elongation in several steps catalyzed by 
fatty acid synthase (FASN), which possesses 7 enzymatic sites 128. FASN synthesises 
palmitate (16:0), a 16-carbon, saturated fatty acid (i.e., lacking double bonds). 
Palmitate may be further elongated by elongases, and/or desaturated by desaturases, 
enzymes introducing double bonds. The desaturase most relevant to this thesis is 
stearoyl-CoA desaturase (SCD1), a ǻ9 desaturase introducing double bond between 
C9 and C10 to yield, if palmitate is the substrate, palmitoleate [C16:1(ǻ9)] 128.  
Three fatty acyl-CoA molecules linked to a glycerol-derived backbone (glycerol-3-
phosphate) form a triglyceride molecule. Two of the three carbon sites of the glycerol 
backbone is acetylated in a reaction catalyzed by glycerol-3-phosphate acyltransferase 
(GPAT; Figure 5.1) and monoacylglycerol acyltransferase (MGAT), forming 
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phosphatidic acid 129. GPAT constitutes the committed step in triglyceride synthesis. 
After dephosphorylation of phosphatidic acid, yielding diacylglycerol (DAG), DAG is 
acetylated by diacylglycerol acetyltransferase (DGAT), producing triacylglyceride 
(triglyceride) 129.  
The anabolic hormone insulin is necessary for both triglyceride synthesis and for 
energy uptake and storage in adipose depots; lipid uptake to adipose tissues depends 
on maintained insulin sensitivity 128. Abnormalities in lipid metabolism and glucose 
dysregulation are intimately related, and obesity is closely correlated with insulin 
resistance 130.   
Figure 5.1 Important steps in fatty acid synthesis (purple), desaturation (orange), triglyceride 
biosynthesis (yellow) and fatty acid oxidation (blue). Taken from 131, with permission. For 
full names of relevant enzymes, see text. 
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5.4.3 Cholesterol metabolism 
The percentage of cholesterol in cellular membranes has significant influence on the 
physical properties and organization of the membrane 132, 133. In addition, cholesterol 
is a substrate for synthesis of complex sterols, such as steroid hormones (e.g. cortisol, 
testosterone and estradiol), and bile acids 134. Like fatty acids and triglycerides, 
cholesterol may be absorbed from the diet or synthesized de novo in the liver. De 
novo synthesis of cholesterol is a complex pathway, with hydroxymethylglutaryl-
Coenzyme A reductase (HMGCR) as the rate-limiting enzyme  128. Statins, commonly 
used lipid-lowering drugs, are inhibitors of HMGCR 128. For transport and storage, 
cholesterol is esterified, i.e., linked to fatty acids through an ester binding, possible 
because cholesterol contains an –OH group.  Esterification, which decreases 
cholesterol’s lipophilic properties, is catalyzed by the enzyme sterol O-acyltransferase 
(SOAT, also known as ACAT).  
5.4.4 Lipids in the brain  
As mentioned in section 5.2.4, glial cells (oligodendrocytes) produce myelin 
embedding the axons of neurons in the CNS 135. Myelin is rich in cholesterol, which is 
synthesized de novo by glial cells, as cholesterol cannot be transported across the 
blood-brain barrier, and neurons have been thought to possess limited capacity for 
cholesterol synthesis 136, 137. Increasing amounts of data also support the idea that glial 
cells, previously regarded as passive cells whose only function is to maintain neurons, 
may be required for the formation and maintenance of interneuronal synapses in the 
brain 138, 139.  Lipids, among them cholesterol, constitute key components in the 
efficient communication between neuronal and glial cells 133, 138-140. Glial cells secrete 
apolipoprotein E (ApoE)-bound cholesterol, which is taken up by neurons by means 
of low-density lipoprotein (LDL) receptors and acts as a growth factor for neurons 138, 
141, 142. 
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5.4.5 Regulatory factors in lipid biosynthesis 
As Figure 5.1 shows, a large number of enzymes are involved in the synthesis of fatty 
acids and triglycerides. Many of these are primarily regulated at the transcriptional 
level, meaning that transcription of the genes encoding them is regulated in a 
coordinated manner 143. The sterol regulatory element binding proteins (SREBPs) are 
transcription factors involved in numerous aspects of fatty acid, triglyceride, and 
cholesterol synthesis, and are frequently designated “master” transcription factors in 
lipogenesis, as they hold key positions in the coordinated transcription of lipogenic 
genes. Two main SREBP proteins, SREBP1 and SRBEP2, are encoded by two 
distinct genes. The SREBPF1 gene encodes two isoforms, SREBP1a and SREBP1c, 
of which SREBP1c is the isoform most extensively expressed in liver and adipose 
tissues in mice, while SREBP1a is primarily found in cultured cells 144. SREBP1c is a 
main regulator of genes encoding enzymes involved in fatty acid and triglyceride 
metabolism, e.g. the genes encoding ACC1, FASN, SCD1, and GPAM 145-147. 
SREBP2, encoded by SREBF2, controls the transcription of enzymes synthesizing 
sterols, including the rate-limiting HMGCR as well as HMGCS and several of the 
enzymes catalyzing later steps in the cholesterol biosynthesis pathway 147.  
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Figure 5.2 SREBP and its activation. SREBP, constisting of one regulatory domain and one 
domain containing a basic-helix-loop-helix leucine zipper (bHLH-Zip) protein 148. The 
inactive form of SBERP forms a complex with SREBP cleavage activating protein (SCAP), 
a lipid sensor. Insulin-induced gene (Insig) immobilizes the SREBP-SCAP complex in the 
ER when lipid levels are high. Upon cholesterol depletion, SREBP-SCAP is transported to 
the Golgi apparatus, where the bHLH-Zip domain is released, translocating to the nucleus to 
initiate transcription of its target genes. SREBP1 is regulated by numerous nutritional factors 
(e.g. carbohydrates) 149, while SREBP2 is primarily regulated by cholesterol levels. 
Illustration by Johan Fernø.  
The SREBP proteins reside in the endoplasmatic reticulum (ER) membrane as 
inactive precursor proteins of 120-130 kDa. Intracellular sterol depletion or other 
alterations in the cell’s nutritional status result in translocation of the inactive SREBP 
protein to the Golgi apparatus, where proteolytic cleavage produces an active 
(nuclear) form of 60-70 kDa (Figure 5.2) 147. A large number of lipogenic gene 
promoters contain sterol regulatory elements (SRE) or an E-box motif with affinity 
for cleaved SREBPs. As a key regulator of anabolic processes, SREBPs are activated 
in states of energy surplus, such as increased energy intake (in the form of 
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carbohydrates or lipids). Both saturated fatty acids and insulin promotes SREBP1c-
mediated lipogenesis 147, 150, 151.   
5.4.6 Mechanisms of fatty acid oxidation 
When energy mobilization is required, free fatty acids may be released from 
triglycerides by lipolysis, and oxidised in the mitochondria in a process releasing ATP 
128. If energy reserves are depleted, free fatty acids are transported from white adipose 
tissues to skeletal muscle, heart, and liver, for oxidation 152. Oxidation takes place in 
the mitochondrial matrix. Fatty acids, “activated” through linkage to CoA yielding 
fatty acyl-CoA, are linked to carnitine by carnitine palmitoyltransferase 1 (CPT1) 
before being transported across the outer mitochondrial membrane (Figure 5.1). In the 
mitochondrial matrix, the fatty acyl group is transferred from carnitine to a matrix-
specific pool of CoA. The transient linkage to carnitine (carnitine shuttle) represents 
the rate-limiting steps of fatty acid oxidation. In the matrix, fatty acyl substrates are 
oxidised in a four-step process. Oxidation of one palmitoyl molecule (C16:0), which 
is broken down to 8 acetyl-CoA molecules, yields 28 ATP units (in addition, acetyl-
CoA oxidation through the citric acid cycle yields further ATP) 128. Organelles other 
than mitochondria, namely peroxisomes, may also be the site of fatty acid ȕ oxidation, 
catalyzed by different enzymes than those found in mitochondria. In particular, the 
enzyme acyl-CoA oxidase 1 (Acox1), catalyzing the first step in peroxisomal ȕ
oxidation, is important.  
5.4.7 Regulation of fatty acid oxidation and lipid storage 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors sensing 
lipid levels and regulating a wide array of responses to altered lipid load. Three PPAR 
isoforms - PPARĮ, PPARį, and PPARȖ - are recognized, all transcription factors with 
a large number of target genes 152. PPARĮ, highly expressed in the liver, induces ȕ-
oxidation in times of reduced energy access, e.g. in the fasting state. PPARȖ is 
predominantly expressed in adipose tissues, and activates pathways facilitating lipid 
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storage through biosynthesis and adipocyte differentiation. Increased lipid storage 
capacity resulting from PPARȖ activation is thought to be an important mechanism of 
action for the pharmacological PPARȖ agonists thiazolidinediones (TZDs), presently 
used as insulin-sensitizing agents in patients 152. 
Figure 5.3 The structural formula of TTA.
5.4.8 Tetradecylthioacetic acid (TTA) 
Tetradecylthioacetic acid (TTA) is an artificially synthesized fatty acid where the 3rd
carbon atom is replaced with a sulphur atom, producing a non-oxidizable fatty acid 
derivative (CH3-(CH2)13-S-CH2-COOH). Acting as an agonist for all PPAR 
subspecies, with most potent effects on PPARĮ, TTA nevertheless induces the 
mitochondrial ȕ-oxidative apparatus, resulting in increased mitochondrial oxidation 
of naturally occurring substrates for ȕ-oxidation 153. In male rats, TTA has been 
shown to prevent adiposity and insulin resistance induced by high-fat diet, decreasing 
plasma triacylglycerol and free fatty acid levels 153, 154. Fibrates, another type of 
PPARĮ agonists used clinically in the management of hypertriglyceridemia 152, have 
also been shown to improve insulin sensitivity in rodents 155-157. Small clinical trials 
have indicated metabolically beneficial effects of TTA in patients 158, and TTA was 
therefore included in our rat experiments. 
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6. Aims of the study
The overall aim of this study was to identify new molecular mechanisms underlying 
metabolic adverse effects of antipsychotic drugs, and to confirm their relevance by 
means of a rat model.  
Specific aims:  
o To identify differential metabolic effects of different antipsychotic drugs in 
various cultured cell types modelling cell populations in the CNS 
o To clarify the role of hyperphagia in antipsychotic-induced weight gain, in a 
rat model 
o To examine the possible uncoupling of weight gain from alterations in lipid 
metabolism in rat exposed to antipsychotic drugs 
o To explore the use of a non-invasive imaging technique (MRI) for 
quantification of antipsychotic-induced adiposity in rat 
o To examine the development of food intake, weight gain and lipogenic 
alterations in long-term antipsychotic treatment in rat 
o To investigate the lipid-lowering, modified fatty acid TTA as a potential 
pharmacological intervention strategy for metabolic adverse effects 
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7. Summary of results 
Paper I 
The experiments in Paper I were based on results from our initial microarray studies 
in antipsychotic-treated, cultured cells 159, 160. Examining the effects of a number of 
antipsychotics on lipogenic gene expression in human neuron-like and glial-like cell 
types we  found that clozapine, one of the two most metabolically potent 
antipsychotics in humans, and chlorpromazine, the “prototype” first-generation 
antipsychotic, activated the transcription of lipogenic genes with most pronounced 
effects in glial-like cells. Lipogenic activation was mediated by the SREBP 
transcription factor, a master regulator of lipogenesis.  
Paper II 
Rats were treated with olanzapine or aripiprazole for 13 days. As expected, 
olanzapine-treated rats increased their food intake and gained weight in the form of 
increased adipose tissue mass, demonstrated by weighing and MRI-based 
quantification of adipose tissue. Aripiprazole, included as a negative control due to its 
clinical status as metabolically neutral, induced a similar pattern. In an olanzapine-
treated group of rats with limited food access, weight gain was absent. However, 
serum triglyceride levels were increased in both olanzapine treatment groups, as was 
lipogenic gene expression in visceral adipose tissue. Aripiprazole-treated rats did not 
develop these features. We concluded that factors other than weight gain may 
significantly contribute to antipsychotic-induced metabolic derangements.  
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Paper III
Seeking to elaborate our findings from Paper II, we extended the treatment period to 8 
weeks, included two new antipsychotics and slightly lower drug doses. The weight 
gain-inducing effects of olanzapine wore off ~ 3 weeks into the experiment, while 
treatment with clozapine failed to induce weight gain. The modified fatty acid TTA 
potentiated weight gain both in combination with olanzapine and clozapine, with 
concomitant reduction in plasma and liver lipid levels. The lipid-lowering effects of 
TTA were accompanied by substantial increase in the transcription and enzymatic 
activity of the key oxidative enzymes ACOX1 and CPT2 in the liver, as well as 
reduced transcription of the rate-limiting enzyme in cholesterol, HMGCR. While 
calling the relevance of the female rat model into question, the results supported the 
concept of weight-lipid uncoupling. 
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8. Discussion
8.1. Methodological aspects 
8.1.1 Cell culture 
In paper I, we examined potential lipogenic effects of antipsychotic drugs in five 
different cell cultures. The use of cell cultures is extremely widespread in biological 
research. Among the numerous advantages of using cultured cells are the easily 
controlled environment, e.g. availability of nutrients, and flexible experimental 
setups, e.g. regarding drug doses. Furthermore, working with cell culture circumvents 
most ethical considerations. However, even though cultured cells interact, traditional 
cell cultures represent a considerable oversimplification, since interaction between 
different cell types usually present in an organ, as well as tissue-tissue interaction, are 
absent. In addition, cells are usually transformed, usually malignantly, in order to 
enable division and growth in culture. In many instances, such “non-physiological” 
conditions are necessary in order to discriminate relevant molecular processes from 
feedback responses and other compensatory events normally present in a complete 
organism. Using two neuron-like (HCN2 and SH-SY5Y) and two glial-like (GaMg 
and CCF-STTG1) human cell lines, as well as one hippocampal primary culture from 
rat (R-Hi-501), we found corresponding upregulation of SREBP target genes in all 
cell types, but with minor effects in cells derived from neurons. The common pattern 
observed across cell lines indicated that antipsychotic-induced SREBP activation 
observed in GaMg cells in our previously published article 159 is not limited to one 
type of cultured cells, and could represent a generalized drug effect.  
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8.1.2 RealTime PCR  
In order to quantify expression levels of potentially relevant genes in both cell culture 
and in rat tissues, we have extensively used RealTime PCR. This method is based on 
the concept of a fluorescent probe or a DNA-binding dye being released as mRNA is 
replicated throughout 35-40 PCR cycles. Continuous quantification of released probe 
or dye permits “real-time” quantification of mRNA levels 161. The PCR cycle during 
which the level of probe or dye is first detected at a higher level than the sample 
background represents the gene’s cycle threshold (Ct) value 161. The RealTimePCR 
method is highly sensitive to alterations in gene expression across a wide range of 
expression levels, i.e. even for genes with particularly high or low expression levels in 
a certain tissue 161. We used SYBR® Green, a DNA-binding dye, and primers 
designed in-house, for all RealTime reactions. For analysis of results, we used the 
comparative Ct method (2-ǻǻCt method), with normalization towards one or more 
endogenous control genes. Here, the relative difference in gene expression between 
antipsychotic-treated samples and vehicle-treated samples, with the latter used as 
calibrator, was calculated based on the genes’ Ct values. This method assumes similar 
replication efficiencies between genes, controlled by means of serial dilutions, and is 
more reliable if PCR products are kept below 150 bp. We therefore designed utilized 
primers such that the PCR product size was kept below this size for all genes.   
In order to control for differences in RNA input in the reverse transcription stage, Ct 
values for all target genes were normalised to Ct values for genes thought to be stably 
expressed in target tissues (i.e. housekeeping genes). Selection of endogenous control 
genes is a major challenge when using RealTime PCR, and the expression of several 
housekeeping genes have been shown to be affected by drug exposure in cell culture 
162.  
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Figure 8.1 Ct values (Y axis) for 7 potential endogenous control genes in white adipose 
tissue from rats exposed to different pharmacological treatments. Each data point represents 
one sample. Samples were taken from rats exposed to different pharmacological treatments. 
Each coloured curve represents one potential reference gene. Arrows signify the two 
endogenous control genes used in our rat experiments.  
Preparing to analyze tissues not previously examined in our lab (particularly white 
adipose tissues), we ran selected samples on predesigned panels (low density arrays, 
LDA; Applied Biosystems) containing several pre-selected endogenous control genes 
commonly used (Figure 8.1; unpublished data), in order to select stably expressed 
housekeeping genes. Based on LDA results, candidate genes for further use as 
endogenous controls were chosen and further evaluated using different RealTime 
assays. The reference gene used in Paper I, ribosomal protein, large, P0 (Rplp0; 
designated P0 in Paper I-III) in addition to the commonly used ȕ-actin, were selected 
for use in further analyses, and these two reference genes were run in each new batch 
of cDNA in the rat experiments. In order to detect potential systematic treatment 
effects on endogenous control genes, Ct values in vehicle- and antipsychotic-treated 
rats were habitually compared for all examined genes during analysis of RealTime 
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PCR data. Results from several biological replicates have confirmed our initial 
patterns of transcriptional regulation by antipsychotic agents, increasing the validity 
of results. Furthermore, several key findings were validated at the protein level using 
Western blots.  
8.1.3 MRI-based quantification of adipose tissue volume 
Paper II includes tissue imaging data collected using a 7T MRI scanner. Olanzapine- 
and aripiprazole-exposed rats included in a 2-week experiment underwent MRI 
scanning prior to the initiation of treatment, and by the end of the treatment period. 
The protocol used for image analysis was developed by in-house collaborators. In the 
attempt to extract quantitative data (adipose tissue volumes) from MRI images, two 
major challenges deserve mention. Firstly, in order to quantify alterations in white 
adipose tissue mass between two time points, one needs reliable anatomical 
landmarks. Scanning the entire animal was not an option, as this would require an 
unreasonable amount of time (considering both time spent in anaesthesia and 
experimental logistics). As MRI is not a sensitive method for imaging of skeletal 
parts, the early idea of using lumbar vertebrae as landmarks was dismissed. Instead, 
we chose to use the easily visible kidneys.  A second challenge was the distinction 
between white adipose tissue and artefacts, particularly in the intestine. The 
segmentation protocol developed to distinguish and quantify adipose tissue yielded a 
relevant impression of increased adipose tissue volume in olanzapine-treated rats, but 
numerical estimates were not significantly correlated with dissected adipose tissue 
mass (Paper II). The reasons behind this discrepancy remain unclear. In further 
developing MRI acquisition and analysis, a natural first step would be to increase the 
anatomical area examined, e.g. by scanning the entire abdominal area. Alternative 
methods (e.g. dual-energy X-ray absorptiometry [DXA] scans) are available for 
quantification of total adipose tissue mass in rodents (reviewed in 163). MRI images 
permit the distinction of different adipose depots (visceral, subcutaneous), and as 
demonstrated by us, rodents could be examined at several time points during the same 
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experiment, with no significant mortality among examined rats. These are among the 
advantages that should encourage further use and development of MRI protocols and 
analysis tools in studies centred on metabolic adverse effects.  
Figure 8.2. Deeply anaesthetized rat mounted for MRI examination, covered by a heating 
mat (blue). Photograph by Silje Skrede.  
8.1.4 Selecting a drug vehicle 
Most antipsychotic agents are close to insoluble in water, but readily dissolved in 
DMSO or alcohol. Concerns over toxicity, vehicle-induced biochemical effects 
confounding results, and palatability issues led us to search for an appropriate vehicle 
for use in rat studies involving oral administration of antipsychotics. Eventually, 
based on our own experiments and relevant literature, 4% carboxymethyl cellulose 
(CMC) was chosen 114, 117. Antipsychotics were suspended, not dissolved, in the CMC 
solution. As the drugs rapidly precipitated, frequent resuspension was necessary in 
order to maintain the correct drug concentration during administration to rats, 
potentially introducing dosing inaccuracy. Measurements of serum drug levels 
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showed modest variation across antipsychotic-treated rats at the time of sacrifice, 
indicating adequate dosing of drug suspended in CMC.  
8.2 Modelling metabolic adverse effects in rat 
8.2.1 Divergent findings in human and rat  
As mentioned in the Introduction (see Table 5.5), several aspects of metabolic adverse 
effects diverge in rodent and human, primarily considering gender differences 
(observed in rat, not convincingly demonstrated in humans) and dysmetabolic 
potencies between different antipsychotic agents. In particular, the near absence of 
metabolic alterations in clozapine-treated rats remains puzzling.  
The question of gender specificity raises the question of whether endocrine factors 
may play a more significant role than has been demonstrated thus far. Antipsychotics, 
as recognized dopamine receptor antagonists, are known to increase prolactin levels 
in patients 164, 165. Olanzapine has been demonstrated to increase serum prolactin 
levels both in female 117, 124 and in male rat 105, 166, indicating that hyperprolactinemia 
per se cannot provide a straightforward explanation for the gender pattern observed in 
rat. Oestrogens are closely linked with distribution of adipose tissue as well as several 
other aspects of energy metabolism 167, and may be relevant to the gender differences 
observed in rat. One study found unaltered serum oestradiol levels in female, 
olanzapine-treated rats 124. In ovariectomized rats, with negligible oestradiol levels, 
olanzapine has still been demonstrated to induce food intake and weight gain 168. In 
patients, olanzapine treatment had no effect on oestradiol levels, neither in males 169
nor in females 170. Even though other endocrine factors could be relevant, there are no 
obvious candidates in the relatively limited number of studies examining hormonal 
effects of antipsychotics with high dysmetabolic potential 171.   
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During the last few years, a quite differentiated picture of antipsychotic-induced 
alterations in rodents has emerged. For instance, increased adiposity in spite of 
constant body weight after subchronic olanzapine treatment of male rats has been 
described in several studies 105, 106. Through these, and our subchronic experiments 
demonstrating olanzapine-induced serum triglyceride elevation, an increased number 
of shared features in human and rodent may emerge, adding to the relevance of rodent 
models. Nevertheless, in further development of animal models for antipsychotic-
induced metabolic adverse effects, several important challenges remain.  
8.2.2 Challenge I: pharmacokinetics of antipsychotics in rat 
In rat, metabolism of antipsychotic agents differs significantly from human 
metabolism of these drugs. For instance, the half-life (t1/2) of clozapine in rat serum is 
1.5 hours, while the average t1/2 is 10 hours in human 172, 173. Similar differences are 
found for olanzapine, with a t1/2 of 2.5-3 hours in rat, compared to an average of 30 
hours in human 174-176. The rapid metabolism of antipsychotics in rat complicates the 
selection of appropriate drug doses in rat experiments, as serum drug concentrations 
rapidly reach negligible levels.  
8.2.3 Challenge II: dosing of antipsychotics in rats 
Defining a “correct” dose for antipsychotics in rats based on clinical observation is 
difficult. A commonly used approach when selecting doses for rat experiment is direct 
transfer of doses used in patients. In many countries, the maximum olanzapine dose 
approved for use in patients is 20 mg, i.e. ~0.3 mg/kg in a person weighing 70 kg 177. 
As for clozapine, patients may receive 600 mg, i.e. ~8.6 mg/kg 177. In rats, these doses 
are too low to induce weight gain 108, 109, 111, 178. Based on the significant differences in 
human and rodent drug metabolism, a dosing strategy based on the percentage of D2
receptor occupancy in the CNS has been suggested 179. In order to achieve D2
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occupancy comparable with that observed in humans (65-80% for olanzapine and 45-
65% for clozapine) after a single dose of antipsychotic agents in rat, olanzapine doses 
in the range of 1-2 mg/kg and clozapine doses of 5-15 mg/kg have been 
recommended 179. As mentioned in the Introduction, raising clozapine doses in rats to 
this level has so far not yielded weight gain. In fact, in one subchronic study rats 
received 30 mg/kg clozapine, with absence of weight gain 180. Notably, in male rats 
receiving 20 or 40 mg/kg clozapine, D2 occupancy in the CNS was far below the 
levels observed in humans at clinically relevant doses; body weight was not measured 
181. High doses (olanzapine: ~ 20 mg/kg; clozapine: 10-20 mg/kg?) may cause 
sedation 108, 182, and this fact has influenced the doses selected for studies in rodents. 
Some studies, however, reported absence of sedation in rats in the 20-40 mg/kg 
clozapine dose interval 180, 181.  Thus, underdosing may represent an explanation for 
the lack of weight gain in clozapine-treated rats. 
A second dosing-related issue is drug tolerability. In patients, weight gain is typically 
considered to continue for approximately one year 183, 184 before body weight reaches 
a plateau, although this issue is debated (reviewed in 100, 185). Weight gain in rats 
treated with low to moderate doses of olanzapine (1-6 mg/kg) seems liable to dwindle 
during treatment, as indicated by our results, with dampened effects on weight gain 
after 2-3 weeks of treatment Papers II, III), although one group showed continued 
weight-inducing effect of olanzapine 1,5 mg/kg for 8 weeks 113. A stepwise increase 
of olanzapine doses, from 4 to 20 mg/kg, potentiated weight gain compared to our 
results, but at 33 days, cumulative weight gain for rats treated with control substance 
and olanzapine (end dose 20 mg/kg) was nevertheless relatively similar 108. Stepwise 
dose increase may, however, circumvent sedation, and should be considered in long-
term rat experiments.  
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8.2.4 Challenge III: administration of antipsychotics to rats 
Administration of antipsychotics to rats is commonly achieved by means of 
subcutaneous or intraperitoneal injections 124, 186, oral administration through gavage 
102, through food 106 or through drinking water 105, 181. As the number of daily 
injections is, for practical reasons, limited, and food/water intake is unevenly 
distributed throughout the light/dark phases, all these approaches are likely to result in 
fluctuating serum concentrations during a 24-hour period 181. Several antipsychotic 
agents degrade when exposed to light, further complicating the approach of mixing 
drugs with food or drinking water. In order to ensure constant delivery of non-
degraded antipsychotics, some researchers have utilized osmotic minipumps, with 
subcutaneous or intraperitoneal implantation of a syringe constantly delivering a fixed 
dose of dissolved drug. As pumps previously needed to be refilled frequently due to 
drug degradation, the use of osmotic minipumps could be more labour-intense than 
anticipated 187. Implantation of syringes carries a risk for infection, and minipumps 
are subject to mechanical failure. In carefully controlled conditions, using light-
protected minipumps, dissolved olanzapine has been demonstrated to remain stable 
for 42 days 188. When successful, serum drug concentrations reached by means of 
minipumps are higher and more stable than those achieved through other means of 
administration 118, 188. The use of minipumps, therefore, may be preferable to 
intermittent oral dosing or injections. Other potential strategies include pellets 
designed for subcutaneous implantation, followed by constant drug release, which are 
available, but have not been extensively used 189.  
8.2.5 Challenge IV: the influence of diet 
Standard rat chow used in laboratories is very high in carbohydrate (40-50%), with a 
low fat content (~5%). In male, olanzapine-treated rats and in female, clozapine-
treated rats, the limited number of studies demonstrating weight gain included chow 
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with high fat content 110, 119, 190. Some studies with very similar setups, however, have 
not yielded significant weight gain 106, 190, 191. Finding the “ultimate” dietary 
composition may not be sufficient to achieve weight gain in male rats treated with 
olanzapine or in clozapine-treated rats, but is likely to represent one of several 
necessary conditions.  
8.2.6 Steps towards increased reliability of rat models 
The possibility remains that a certain constellation of drug dose, mode of 
administration, and dietary fat content will lead to successful replication of a more 
“human-like” pattern of antipsychotic-induced metabolic adverse effects than has 
previously been achieved. In two recently described experiments, male rats were fed 
high-fat chow and treated with 1.5-10 mg/kg olanzapine administered by minipumps; 
still, only marginal effects on body weight gain were observed, in spite of increased 
adipose tissue mass 188, 192. Experiments including even higher antipsychotic doses 
than previously administered to rats may be a natural next step. Of course, one can 
ask whether the need to “fine-tune” several parameters will yield a sufficiently robust 
model - even if clozapine-induced weight gain is successfully modelled, the fact may 
remain that some as yet unrevealed property distinguishes metabolic effects of 
olanzapine in rat from that of clozapine.  
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8.4. Molecular mechanisms of metabolic adverse effects 
8.4.1 Hyperphagia is the main cause of body weight gain 
Weight gain may be caused by increased energy intake, reduced energy expenditure, 
or a combination of the two. In order to investigate the role of food intake in 
olanzapine-induced weight gain, we included olanzapine-treated, pair-fed treatment 
groups in our rat experiments. Pair-fed rats were offered an amount of chow 
corresponding with the average amount consumed by control animals during the 
preceding 24 hours, typically 15-16 grams per rat. Freely fed olanzapine-treated rats 
may consume 20-24 g of chow during 24 hours. We observed that olanzapine-treated 
rats with free access to chow rapidly gained weight, while pair-fed rats did not gain 
weight, or even gained less weight than control animals (Paper II). This led us to 
conclude that increased food intake (hyperphagia) is the main driving force behind the 
observed weight gain, in agreement with previous rat studies 88, 121 as well as clinical 
studies 193, 194. Our MRI studies, coupled with dissection and weighing of adipose 
tissues, demonstrated that weight gain occurred primarily in the form of increased 
adipose tissue mass, also in agreement with previous results in rat (Table 5.5) 103, 124
and in patients 60, 61. The pair-fed rats in our experiment did not show signs of 
increased adipose tissue mass. In an article not included in this thesis, our group has 
explored the possible mechanisms of antipsychotic-induced hyperphagia, 
demonstrating increased levels of appetite-stimulating neuropeptides in hypothalamus 
195. 
8.4.4 The role of energy expenditure in weight gain
In addition to increased energy intake, reduced energy expenditure may contribute to 
weight gain. As previously mentioned, sedation resulting in reduced physical activity 
is a recognized adverse effect of antipsychotic agents. We did not, however, observe 
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significant sedation in the experiments described in Paper II. If sedation contributed 
significantly to weight gain, the obese phenotype would have been expected to be 
present in the olanzapine pair-fed treatment group.  
Rodents possess brown adipose tissue, which is able to convert surplus energy to heat 
through a process termed thermogenesis 196. Reduced thermogenesis, measured as 
reduced protein levels of uncoupling protein 1 (UCP1), has been reported in pair-fed, 
olanzapine-treated rats which gained weight, in contrast to pair-fed rats in our 
experiments 197. In a previously mentioned study, olanzapine treatment did not induce 
altered thermogenic rates in brown adipose tissue from rats with stable body weight, 
but increased adiposity 178.  Based on these conflicting findings, we examined the 
expression of UCP1, PPAGȖ, and peroxisome proliferator activated receptor gamma 
coactivator 1Į (PGC1Į), important markers of thermogenesis, in brown adipose tissue 
198. Several of these markers were downregulated in both ad libitum-fed and pair-fed 
olanzapine groups, possibly signifying reduced thermogenesis. Although synergistic 
effects of hyperphagia and reduced thermogenesis in the olanzapine ad libitum-group 
cannot be ruled out, the lack of weight gain in the olanzapine pair-fed group 
demonstrated that reduced thermogenesis alone did not significantly contribute to 
weight gain in our experiments. In our 8-week experiment (Paper III), TTA 
monotherapy downregulated PGC1Į and UCP1, while no weight gain was observed 
in this treatment group. In olanzapine-TTA treated rats, PGC1Į was also 
downregulated, possibly contributing to the weight gain observed in this treatment 
group. 
Adult humans were formerly thought to lack brown adipose tissue. In recent years, 
however, the presence of brown adipose tissue in adults has been demonstrated by 
means of PET scans 199-201. Brown adipose tissue may play a significant role in human 
metabolism, and should not be ignored when examining energy balance 201. 
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8.4.5 The role of fatty acid oxidation in antipsychotic-induced metabolic adverse 
effects 
Reduced capacity for fatty oxidation could, theoretically, induce energy surplus and 
thus obesity. Examining the expression of ACOX1, CPTs, and PPARs in liver and 
white adipose tissues from subchronically treated rats (Paper II) or from chronically 
treated rats (Paper III), we found no evidence for reduced oxidative capacity induced 
by olanzapine or clozapine. The lipid-lowering effects of TTA, on the other hand, 
were likely related to the sharp increase observed in hepatic ACOX1 and CPT1 
transcription and activity.  
8.4.6 “Uncoupling” of body weight and serum lipid levels  
Hypertriglyceridemia is known to correlate with obesity, in particular with the amount 
of visceral adipose tissue. However, the existence of both “obese, but metabolically 
healthy” and “metabolically obese” populations is now recognized 202. The latter 
group is characterized by normal BMI, but still present with dyslipidemia and reduced 
insulin sensitivity 203. In paper II, through the introduction of pair-fed treatment 
groups, we found that olanzapine-treated rats developed elevated levels of serum 
triglycerides without concomitant adiposity. These results were further supported by 
results in paper III, in which olanzapine-TTA treated rats gained weight, while 
nevertheless developing lowered serum and liver levels of cholesterol and 
triglycerides, resulting in lipid profiles not expected in rats with this degree of obesity.  
Interestingly, early clinical findings, both of chlorpromazine-induced increase in 
serum cholesterol levels and olanzapine-induced increase in serum triglyceride levels, 
indicated that serum lipid levels in patients were not simply raised secondary to 
weight gain 52, 65. Several recent clinical studies have also presented evidence for 
increased serum triglycerides independent of weight gain 204-206. In the CAFE study, 
patients treated with quetiapine experienced the least increase in weight gain; in spite 
50
of this, increase in serum triglycerides and total cholesterol were most pronounced in 
this treatment group 207. Of note, in a “drug switching” study in which patients 
changed from olanzapine to aripiprazole treatment, a significant reduction in serum 
triglycerides occurred rapidly after the switch, while weight loss occurred more 
gradually, indicating that triglyceride levels did not simply decrease in parallel with 
body weight 208. To our knowledge, no animal studies other than our own have 
investigated the potential uncoupling between weight gain and increased serum lipids.  
8.4.7 Antipsychotic-induced, SREBP-mediated lipogenic activation in cultured 
cells  
In addition to our papers describing antipsychotic-induced SREBP activation in 
GaMg cells, our research group published a work demonstrating similar effects in 
human liver cell lines (THLE-3 and HepG2) 160. Several studies in cell culture have 
subsequently supported our finding of antipsychotic-induced SREBP activation in 
cells, including adipocyte cultures and primary hepatocytes 209-212. In paper I, we 
demonstrated that antipsychotics induce both SREBP1 and SREBP2 target genes. We 
showed increased proteolytic cleavage of SREBP2, i.e. activation at the protein level, 
and upregulation of the genes encoding the SREBP1a and SREBP2. The exact nature 
of the interaction between antipsychotic agents and the SREBP system remains 
unclear, but may be related to hampered intracellular cholesterol transport through 
direct interaction between drugs and intracellular membranes 213, 214. Chlorpromazine, 
which was demonstrated by us to induce cholesterol biosynthesis genes in GaMg 
cells, is a tricyclic cationic amphipathic drug with both lipophilic and hydrophilic 
chemical properties 215. Several antipsychotics, among them clozapine, also possess a 
tricyclic structure, and have been demonstrated to directly interact with the cholesterol 
biosynthesis pathway 212, 215-217. Possibly, reduced ER cholesterol causes “imaginary” 
lack of intracellular cholesterol, inducing SREBP translocation, maturation and thus 
target gene transcription. Recently, an antipsychotic-induced ER stress response 
(unfolded protein response) has been suggested to contribute to SREBP activation, 
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offering a potential explanation for the activation of both SREBP isoforms, which are 
differentially regulated in the physiological setting 218.  
8.4.8 Antipsychotic-induced lipogenic activation in rodents and humans 
Prior to our subchronic studies, we performed acute experiments on clozapine and 
olanzapine treatment in rats. We found short-term lipogenic effects, most notably 
significant hepatic lipid accumulation, accompanied by an early transcriptional 
activation followed by sustained downregulation of lipogenic genes in liver and 
adipose tissues 219, 220. These observations illustrate the presence of potent negative 
feedback mechanisms complicating interpretation of direct pharmacological effects of 
antipsychotics in rat. In our two-week studies with moderate olanzapine doses (Paper 
II), feedback mechanisms were partly circumvented through the reduction of drug 
doses and repeated exposure, and we demonstrated weight-independent upregulation 
of several SREBP1c target genes in liver and in visceral adipose tissue. 
Corresponding upregulation of Fasn has previously been demonstrated in adipocytes 
from male, olanzapine-treated rats that did not gain significantly more weight than 
control animals during 5 weeks of treatment, but developed increased adipose tissue 
mass 107. Furthermore, in our subchronic study (Paper II), we found signs of 
SREBP1c activation in the liver, both at the transcriptional and at the protein level. In 
agreement with other studies, serum levels of monodesaturated fatty acids were 
increased, indicating elevated desaturase activity 221, 222. Upregulation of Scd1 
transcription is notable, as this desaturase has been suggested to represent a key 
branch point in lipid biosynthesis, directing lipids towards triglyceride or cholesterol 
ester formation (i.e., lipid storage) 223.  
In visceral adipose tissue, in spite of upregulation of several recognized SREBP1c 
target genes, Srebpf1 transcription or SREBP1c activation at the protein level were 
absent. In fact, there are indications that in adipocytes and adipose tissues, SREBP1c 
excerts less profound effects on the transcription of its classic target genes than in the 
liver 224-227. Other, as of yet unrevealed, mechanisms may contribute to olanzapine-
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induced lipogenic activation in adipose tissues. As lipogenic upregulation was present 
in olanzapine pair-fed rats, this induction is likely to represent a pharmacological 
effect of olanzapine, not a consequence of hyperphagia and obesity.  
In conclusion, we found partial overlap of results in cell culture and animal models, 
underlining the complexity of lipid metabolism in the “real-life” setting. SREBP-
mediated lipogenesis may be relevant for dyslipidemic adverse effects of 
antipsychotics, independent of hyperphagia and weight gain. Further experiments are 
required in order to examine potential subchronic effects of clozapine on lipogenesis, 
the relationship between lipogenic activation in metabolic tissues and the elevation of 
serum triglycerides, to identify the factors mediating lipogenic effects of 
antipsychotics in adipose tissues, and to perform relevant clinical studies. 
Interestingly, a clinical pilot study demonstrated elevated transcription of the genes 
encoding FASN and SDC1 in blood cells from olanzapine-treated patients 228. 
8.5. Clinical aspects related to lipogenic activation by 
antipsychotics 
8.5.1 Do metabolically potent antipsychotic agents have superior clinical 
efficiacy? 
Whether some antipsychotic agents are more efficient than others in relieving either 
positive or negative symptoms of schizophrenia - in particular, whether second-
generation antipsychotics are more efficient than first-generation drugs - has been 
extensively debated 229-237. Results from several large clinical studies, among them the 
CATIE and CUtLASS studies, indicate that despite trends towards superior efficacy 
of olanzapine on certain outcomes (primarily time to treatment discontinuation), 
atypical antipsychotics are not convincingly superior to first-generation antipsychotics 
in terms of overall clinical efficiency or quality of life scores 177, 233, 238, 239. As 
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previously mentioned, several reports have documented the superior efficacy of 
clozapine in treatment-resistant schizophrenia 42, 177. In fact, a large population-based 
Finnish study demonstrated significantly reduced mortality in patients treated with 
clozapine compared to patients treated with other antipsychotics, in spite of 
clozapine’s metabolic risk profile 240; this study subsequently received criticism for 
strongly confounded analyses 241.  
Comparisons of typical and atypical antipsychotics are complicated, among other 
issues, by differences in dosing and adverse effect profiles. For instance, motor 
effects of typical antipsychotics could result in the impression that patients suffer 
from more severe negative symptoms 242. Potential interests of the pharmaceutics 
industry must also be kept in mind when evaluating treatment effects 243. In general, 
issues such as adverse effect profile, former response to medication, patient 
satisfaction, cost-effectiveness, and clinicians’ former experiences are significant 
issues when patients with suspected schizophrenia are assigned to a certain 
pharmacological treatment 177, 231, 244. Naturalistic, non-sponsored studies are required 
to further facilitate evidence-based choice of treatment of psychosis 245.  
8.5.2 Are the differences in dysmetabolic potency between different antipsychotic 
agents as substantial as formerly thought?  
As mentioned above, adverse effect profile constitutes an important consideration 
when selecting an antipsychotic, particularly for patients experiencing their first 
episode of symptoms. Therefore, a balanced image of adverse effect profiles is 
required. In paper II, as expected, we found a significant stimulatory effect of 
olanzapine on food intake and weight gain in female rats. Aripiprazole, believed to be 
metabolically neutral in humans, was included as a negative control, and both in our 
subchronic and in our chronic (8-week) experiment (Paper III), aripiprazole showed 
hyperphagic and weight-inducing potential. One former experiment in female rat 
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resulted in aripiprazole-induced weight gain (aripiprazole dose 4-8 mg/kg) 103, while a 
long-term experiment yielded no weight gain (aripiprazole dose 2.25 mg/kg) 113. This 
could indicate that body weight in female rats is more easily affected by 
pharmacological treatment than body weight in human subjects. On the other hand, 
could these results be transferred back to the clinical setting, helping to define a more 
differentiated picture of the dysmetabolic potential of individual antipsychotics? It is 
quite obvious that in patients, some antipsychotics - particularly clozapine and 
olanzapine - induce more potent weight gain, dyslipidemia and insulin resistance than 
other agents. Furthermore, the switching of treatment from olanzapine, quetiapine, or 
risperidone to aripiprazole in patients led to significant improvemens in body weight 
and lipid parameters 74, 208. However, it is obligatory to keep in mind the fact that a 
majority of clinical data is obtained through studies involving previously medicated 
patients, which may significantly influence results. The value of data collected in 
previously unmedicated patients is gaining increasing attention 246. For instance, 
quetiapine and risperidone, have been shown to cause significant weight gain (7% of 
pre-tratment body weight) after 1 year of treatment in 50% of treatment-naïve patients 
receiving quetiapine, and in 58% of treatment-naïve patients receiving risperidone 62, 
207. Similarly, aripirazole, quetiapine and risperidone all caused weight gain in 
adolescent patients 247. As agents such as quetiapine and aripiprazole have been in 
clinical use for an increasing number of years, more data concerning their metabolic 
adverse effects will accumulate, and results from rat experiments may turn out be 
more relevant than they presently appear.  
8.5.3 Are clinical improvement and metabolic adverse effects correlated, 
independent of antipsychotic agent?  
As discussed in paragraph 8.5.1, no sound conclusion has been reached regarding 
superior efficacy of individual antipsychotics. The idea of a link between symptom 
relief and metabolic adverse effects has been a recurrent issue for decades of research 
on antipsychotics. In 1967, an article concerning patients treated with chlorpromazine 
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stated that serum cholesterol levels were positively correlated with clinical 
improvement 52. A number of studies, both in patients treated with olanzapine and in 
clozapine-treated patients, have pointed out a similar link between metabolic adverse 
effects, commonly weight gain, and improvement of positive or negative 
schizophrenic symptoms 205, 248-251. One study found a relation between therapeutic 
response and weight gain both in olanzapine and haloperidol treatment groups, most 
pronounced in olanzapine-treated patients 98. Another study, which has received 
criticism for prophylactically administering the anticholinergic drug to benztropine to 
all patients receiving haloperidol, reported positive correlation of serum cholesterol 
and improved cognition in schizophrenic patients across clozapine, olanzapine and 
haloperidol treatment groups 252.  
Findings such as these are highly interesting considering that antipsychotics 
recognized to have the highest incidence of weight gain, hyperlipidemia and glucose 
dysregulation remain widely used 85. However, some studies have failed to detect 
correlation of clinical state and metabolic adverse effects; for instance, analyses of 
data from the CATIE study resulted in drug-independent association between 
increased BMI and improvement, but the effect size was deemed too subtle to be 
clinically significant 205, 253. Furthermore, lack of correlation between clinical 
improvement and weight gain has been reported in clozapine-treated patients 254, 255. 
A recent study in hospitalized psychotic patients found that quetiapine, which is less 
metabolically potent than olanzapine, was more efficient than olanzapine in reducing 
several treatment outcomes 245. Several issues complicate correlation analyses of 
metabolic adverse effects and clinical improvement. For instance, regain of self-care 
(including increase in food intake), could precede weight gain. No mechanistic link 
has yet been suggested between clinical response and metabolic adverse effects, but 
antipsychotic-induced lipogenesis is highly interesting in this context. 
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8.5.4 Lipogenesis as a possible therapeutic mechanism of action 
As mentioned in the Introduction, demyelination (decreased volume or disrupted 
function of white matter) is presently thought to play a significant role in the 
development of schizophrenia, and may be of particular importance with regard to 
negative symptoms 18, 256-258. Oligodendrocytes, the cells primarily responsible for 
myelin production, synthesize cholesterol, an essential component of myelin, as 
cholesterol is not imported to the CNS 133, 137. Interestingly, a physiological role of the 
SREBP transcription factors in the CNS is emerging (reviewed in 259). Lipid 
synthesis, controlled by both SREBP1 and SREBP2, in different subtypes of glial 
cells is thought to be important both in myelination and various aspects of neuronal 
development, such as synaptic plasticity. For instance, SREBP1 and SCD1 activation, 
correlated with oleic acid synthesis in astrocytes, may be involved in neuronal growth 
and differentiation 259. Thus, alterations in lipid metabolism in the CNS may be highly 
relevant in light of the demyelination, as well as other aspects of neuronal 
dysfunction, observed in patients with schizophrenia. Indeed, myelin-related genes 
have been shown to be downregulated in prefrontal cortex from patients 260, 261. In 
paper I, we demonstrated that SREBP2-activating effects of antipsychotics were more 
potent in glial-derived cells than in cells derived from neurons. A similar study on 
antidepressant drugs yielded comparable results 262. Consequently, our results 
demonstrating antipsychotic-induced induction of lipid metabolism may be relevant 
both to the clinical and adverse effects of these drugs. In fact, the potential effects of 
antipsychotic agents on myelination have been investigated in a rodent model for 
demyelination, where the copper chelator cuprizone was used to pharmacologically 
induce demyelination. In rats treated with cuprizone, which developed phenotypic 
features reminiscent of negative symptoms of schizophrenia, downregulation of 
oligodendrocyte markers was demonstrated in the prefrontal cortex 263. In another 
experiment on mice, clozapine and quetiapine was found to prevent loss of myelin 
induced by cuprizone 264. In male patients with schizophrenia, treatment with 
risperidone led to increased myelination, as quantified by means of MRI 265, 266. A 
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recent review by the first author of the latter article states that “[…] widely used 
psychotropic treatments have under-appreciated CNS metabolic and neurotransmitter 
effects on myelination, its plasticity, and repair that may substantially contribute to 
their mechanisms of action”  267. The possible relation between clinical efficacy and 
metabolic adverse effects is intriguing, and the results discussed above underline the 
fact that avoiding all use of antipsychotics with metabolically unfavourable adverse 
profiles does not provide an easy solution to the huge clinical challenge represented 
by metabolic adverse effects.  
8.5.5 Potential intervention strategies in patients with antipsychotic-induced 
dysmetabolism  
88% of patients with dyslipidemia identified in the CATIE study population received 
no lipid-lowering treatment 79. In general, secondary prevention of metabolic 
complications of antipsychotic treatment appears to have received little attention. 
Clinical studies have suggested that adjunctive treatment with metformin may have 
beneficial effect on insulin sensitivity and body weight 268-270. Statins, i.e. inhibitors of 
HMGCR, have been demonstrated as efficient in antipsychotic-induced dyslipidemia 
271. Notably, metformin indirectly inhibits HMGCR through the activation of AMPK 
272, meaning that both classes of agents regarded as candidates for efficient 
intervention act on the rate-limiting step in cholesterol synthesis.  
Prior to pharmacological intervention strategies, information regarding hyperphagia 
and the risk of developing metabolic adverse effects should be given; patients may be 
surprisingly accessible to educational measures 273. A few relatively small studies 
have addressed the effect of healthy dietary habits and exercise, and found promising 
effects 274-276. Combining behavioural and pharmacological intervention strategies 
could probably reduce the risk for cardiovascular disease in patients receiving 
antipsychotic agents, but it is difficult to imagine that other measures than newly 
developed, clinically efficient drugs with negligible adverse effects will reduce risk 
levels to those found in the general population.  
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9. Concluding remarks 
In selecting the correct treatment for psychotic, delusional or cognitively impaired 
patients, a substantial responsibility rests on the carer. Patient compliance is more 
crucial and challenging in schizophrenia than in many somatic conditions, and 
facilitating compliance greatly reduces the risk of relapse. Risk-benefit considerations 
must rely on solid evidence for clinical efficiency and adverse effects. A survey of the 
massive body of literature published regarding clinical effects of antipsychotic agents 
leaves no definite conclusion with regard to superior clinical efficacy of individual 
antipsychotics. In terms of adverse effect profiles, though, some antipsychotics are 
clearly more metabolically potent than others.  Quite a few authors have pointed to a 
correlation of clinical improvement with the degree of metabolic adverse effects. 
Despite several important confounders, this apparent link is highly interesting in light 
of the essential role of lipid synthesis in the brain. Thus, understanding the 
mechanisms underlying adverse effects is not simply a step towards elimination of 
side effects, but may be necessary in order to develop more efficient antipsychotics. 
Judging by the lack of progress in such development during the last 60 years, the most 
realistic short-term aim will be to develop well-founded strategies for the prevention 
of weight gain, diabetes and dyslipidemia in patients treated with the drugs in 
question. As a complement to dietary measures and physical activity, metformin and 
statins appear to be the best prophylactic candidates.  
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10. Future perspectives 
As mentioned in the Discussion, we recently published an article detailing the 
hypothalamic mechanisms underlying olanzapine-induced hyperphagia. An important 
question is whether the antipsychotics’ lipogenic effects and negative effects on 
glucose metabolism are mediated via the CNS, or whether they occur due to direct 
effects of antipsychotics on peripheral metabolic tissues, such as the liver or adipose 
tissues. Distinguishing primary effects from feedback effects is challenging, and 
specific pharmacological and/or genetic inhibition seems a natural step forward in this 
regard. Such strategies may also strengthen the rationale for prophylactic 
pharmacological intervention for antipsychotic-induced metabolic adverse effects.  
Further work is also necessary in order to increase the scientific and clinical relevance 
of rodent models in this field. In particular, issues such as drug dosing and 
administration should be carefully considered in order to reduce the gap between 
effects of olanzapine and clozapine, as well as gender differences, in rat. An 
improved rat model would facilitate in vivo investigations of the potential significance 
of antipsychotic-induced lipogenesis in myelination.  
Regarding the translational aspects of our work, we plan to search for biological 
markers associated with the use antipsychotic drugs and metabolic adverse effects, in 
patient materials including several hundred patients who will be thoroughly examined 
clinically and biochemically. In one study, patients will be offered follow-up 
appointments for at least a year after starting randomized treatment with either 
olanzapine, amisulpride, or aripiprazole. We will have the opportunity to examine 
DNA and RNA profiles from these patients and, among other outcomes, investigate 
alterations in RNA expression during treatment initiation. Searching for alterations in 
the transcripts described in this thesis, as well as new candidates for further research, 
will be highly exciting. Correlating gene expression with clinical parameters may 
60
enable the identification of biomarkers for clinical response, or for increased risk of 
metabolic adverse effects.  
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